incrementalTreatment update
Tocilizumab case reports expand treatment options for refractory TRAPS
TNF Receptor-Associated Periodic Syndrome →Summary
Multiple case reports have demonstrated tocilizumab efficacy in TRAPS patients refractory to anti-TNF and anti-IL-1 therapies, supporting IL-6 as a pathogenic mediator.
Related treatments
More from TNF Receptor-Associated Periodic Syndrome
significantTreatment update
Long-term CLUSTER extension confirms sustained canakinumab efficacy in TRAPS
significantNew research
French national series quantifies AA amyloidosis severity in TRAPS
significantGenetic finding
INSAID classification system validated for TRAPS treatment decisions
incrementalepidemiology
R92Q prevalence in inflammatory disease cohorts higher than expected
ID: traps-update-4Type: treatment_updateImpact: incremental